Metabolic syndrome in liver transplantation: Relation to etiology and immunosuppression
Top Cited Papers
Open Access
- 29 October 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Liver Transplantation
- Vol. 14 (11), 1648-1654
- https://doi.org/10.1002/lt.21588
Abstract
Excessive weight gain, hypertension, hyperlipidemia, and diabetes are frequently observed in patients having undergone liver transplantation (LTx). These alterations are probably multifactorial in origin, and cluster to generate a metabolic syndrome (MS), increasing the risk of cardiovascular events. We assessed the prevalence of MS (National Cholesterol Education Program‐Adult Treatment Panel III criteria) in 296 LTx patients in the course of regular follow‐up, at least 6 months after transplantation (median, 38 months). Several pre‐LTx and post‐LTx data were collected to identify the factors associated with the presence of MS. In a subset of 99 patients, insulin resistance was measured by the homeostasis model assessment. High blood pressure was present in 53% of cases, hyperlipidemia in 51%, high glucose in 37%, and enlarged waist circumference in 32%. Overall, MS (defined as 3 or more of the above features) was present in 44.5% of cases. Insulin resistance (homeostasis model assessment > 2.7) was observed in 41% of cases. Hypertension and hyperlipidemia were more frequent in subjects on cyclosporine than in tacrolimus‐treated cases, whereas the type of immunosuppressive drug had no effect on the prevalence of diabetes, enlarged waist, and MS. In a logistic regression analysis, only pre‐LTx body mass index (odds ratio, 1.20), body mass index increase (odds ratio, 1.18), and pre‐LTx diabetes (odds ratio, 2.36) predicted MS; age, gender, etiology of liver disease, time from LTx, type of immunosuppressive drug, and previous hepatocellular carcinoma were removed from the model. Disorders related to MS are frequent in LTx patients, and are related to both pre‐LTx conditions and to weight gain. Weight control is mandatory in LTx patients to prevent risk factors of premature atherosclerosis. Liver Transpl 14: 1648–1654, 2008. © 2008 AASLD.Keywords
This publication has 43 references indexed in Scilit:
- Metabolic syndrome in liver transplant recipients: Prevalence and association with major vascular eventsLiver Transplantation, 2007
- Metabolic syndrome following liver transplantation is associated with major vascular eventsLiver Transplantation, 2007
- Metabolic syndrome: A new view of some familiar transplant risksLiver Transplantation, 2006
- Levels of homocysteine are increased in metabolic syndrome patients but are not associated with an increased cardiovascular risk, in contrast to patients without the metabolic syndromeHeart, 2005
- One‐Year Post‐Transplant Weight Gain is a Risk Factor for Graft LossAmerican Journal of Transplantation, 2005
- Diagnosis and Management of the Metabolic SyndromeCirculation, 2005
- Plasma total homocysteine and cardiovascular risk in patients submitted to liver transplantationLiver Transplantation, 2005
- New Onset Diabetes Mellitus in Patients Receiving Calcineurin Inhibitors: A Systematic Review and Meta-AnalysisAmerican Journal of Transplantation, 2004
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Hepatitis C–related cirrhosis: A predictor of diabetes after liver transplantationHepatology, 2000